InDevR Announces Creation of Strategic Advisory Board
Esteemed Group of Leaders in Influenza Preparedness and Biotechnology Business to Help Company Maximize Product Potential
Boulder, CO – SEPTEMBER 30, 2015 – InDevR, Inc., an innovative biotechnology company dedicated to improving diagnostics and vaccine manufacturing, today announced the formation of the InDevR Strategic Advisory Board, an esteemed group of scientific and business leaders chosen to counsel the company on the opportunities for maximizing the impact of its technologies globally.
Kathy Rowlen, Ph.D., Chief Executive Officer of InDevR commented, “With a series of new game-changing technologies now on the market and our FluChip-8G™ system in design and development, the time is right to begin thinking more broadly about the range of business development opportunities available to us.” The new advisors include:
- Nancy Cox, Ph.D. Dr. Cox is the retired Director of the Influenza Division at the Centers for Disease Control and Prevention, and the former Director of its WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza. During her CDC tenure, Dr. Cox helped transform the surveillance and science of influenza viruses and vaccines worldwide. She was the recipient of the Service to America Medals Federal Employee of the Year Award in 2006 and the CDC’s Lifetime Achievement Award in 2014. Time magazine named her one of 2006’s 100 Most Influential People of the Year and Newsweek magazine honored her as one of the “15 People Who Make America Great.”
- Caren Mason. Ms. Mason is the CEO of STAAR Surgical and former CEO of Verinata Health, Quidel Corporation, MiraMedica and eMed Technologies. She has served on several corporate and philanthropic boards, including STAAR, HealthTell, and the Executive Committee of the University of California San Diego Moores Cancer Center Board of Visitors.
- Klaus Stöhr, Ph.D. Dr. Stöhr was until recently Vice President and Head of Global Policy for Novartis Vaccines. Prior to Novartis he worked at WHO, as coordinator of the WHO Global Influenza Program and also as Special Advisor on Influenza Pandemic Vaccine Development for the WHO Initiative for Vaccine Research. He was included in the 2005 Scientific American 50 list of research and policy leaders.
“After decades of working on the science of influenza prevention and control, I am excited to be associated with InDevR, a company with demonstrated commitment to improved influenza diagnosis and development of new tools for more efficient manufacturing of vaccines,” said Dr. Cox. “Their product portfolio has great potential to improve prevention and control of influenza viruses as well as a host of other infectious diseases.”
“InDevR is now at a stage where its products can make a significant contribution to expedited access to seasonal influenza vaccine and more rapid disease diagnosis in people,” said Dr. Stöhr. “InDevR’s new analytical tools for vaccine manufacturing have the potential for faster release and use of pandemic influenza vaccine from many producers in case of a global health emergency.”
“We are excited about the future of InDevR and are delighted that these leaders share in our enthusiasm and recognize the potential for our technologies on a global scale,” continued Dr. Rowlen. “Nancy and Klaus bring an incomparable wealth of knowledge about influenza diagnostics, vaccines, virology, and global trends, and Caren brings tremendous business insight and savvy to aid our mission. I am deeply grateful that these remarkable individuals have joined our efforts.”
The FluChip-8G product in development at InDevR is a multiplexed influenza diagnostic that will enable physicians to identify seasonal influenza viruses and distinguish them from novel potentially pandemic influenza viruses. The development effort is supported by BARDA contract HHSO100201400010C. Over the past two years, the company introduced two new products for vaccine manufacturing: the Cypher One™ system to standardize the hemagglutination inhibition assays that are used to characterize new strains of influenza, and the VaxArray™ Influenza potency assay, a multiplexed immunoassay for hemagglutinin protein quantification. Development of both products was supported by the Small Business Innovation Research (SBIR) program at the National Institutes of Allergy and Infectious Disease (R43 AI106054, R44AI102318, respectively).
Neither HHS, NIAID, CDC nor BARDA are responsible for the contents of this release. The statements contained in this release do not constitute endorsement or recommendation by the U.S. Government.
InDevR has a demonstrated commitment to innovative solutions for the life science industry. With focus on enhancing diagnostics, vaccines and other biotherapeutics, InDevR has emerged as a leader in progressive new analytical technologies that enable accelerated development and manufacturing of these life-saving products. For more information about the company and products, please visit www.indevr.com or call 303-402-9100.